PepGen Prices 25 Million Shares at $5 in $125 Million Offering

Your call?🐂 Bullish🐻 Bearish

The clinical-stage biotech expects $125 million in gross proceeds before underwriting discounts, commissions and offering expenses. Underwriters have a 30-day option to buy up to 3.75 million more shares.